LDL Cholesterol Lipoproteins
CRISPR Therapeutics’ gene editing therapy reduces bad cholesterol and triglycerides by as much as 80%
Gene Modification, Clustered Regularly Interspaced Short Palindromic Repeats, Triglycerides, LDL Cholesterol Lipoproteins, In Vivo, CTX310, Clinical Trials, cholesterol, Genes
AstraZeneca’s oral PCSK9 inhibitor halves cholesterol in phase 2 trial
AZD0780, LDL Cholesterol Lipoproteins, AstraZeneca ‘s, Oral cavity, PCSK9 inhibitor, Effectiveness
NewAmsterdam’s CETP Inhibitor Obicetrapib Achieves Phase 3 Success but Fails to Meet Investor Expectations
NewAmsterdam Pharma, CETP inhibitors, obicetrapib, cholesterol-lowering drugs, Phase 3 trials, investor expectations, LDL cholesterol reduction
NewAmsterdam’s Obicetrapib Hits Primary Endpoint in Phase III HeFH Study, but Falls Short of Expectations
NewAmsterdam Pharma, Obicetrapib, CETP Inhibitor, Phase III Trial, Heterozygous Familial Hypercholesterolemia (HeFH), LDL Cholesterol, HDL Cholesterol, Cardiovascular Disease
Arrowhead Pharmaceuticals Shifts Focus to Plozasiran, Deprioritizes Zodasiran in Cardiometabolic Drug Development
Arrowhead Pharmaceuticals, cardiometabolic drug, plozasiran, zodasiran, RNAi therapies, cardiovascular disease, triglycerides, LDL cholesterol